HER2 Amplification, Miscellaneous Tumor, FISH, Tissue
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Guiding cancer therapy, as patients with HER2 amplification may be candidates for therapies that target the human epidermal growth factor receptor 2 (HER2) protein (eg, trastuzumab [Herceptin], pertuzumab, lapatinib)
Confirming the presence of HER2 amplification in cases with 2+ (low level) or 3+ (high level) HER2 protein overexpression by immunohistochemistry
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
This test does not include a pathology consult. If a pathology consult is requested, 70012 / Pathology Consultation should be ordered and the appropriate FISH test will be ordered and performed at an additional charge.
Reflex testing will be performed using the HER2/D17S122 probe when the HER2:D17Z1 result is equivocal as defined by 2013 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.
Fluorescence In Situ Hybridization (FISH)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
HER2 Amp, Misc. Tumor, FISH
c-erb-b2 Amplification Test